Compare Becton Dickinson and Co (BDX) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $49.41B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.34. The key difference: Becton Dickinson and Co pays a 2.32% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| BDX | MSTZ | |
|---|---|---|
Market Cap | $49.41B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.39 | $27.92 |
52-Week Low | $138.62 | $3.88 |
Enterprise Value | $65.51B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $183.71, up 2.27% today, near its consensus price target of $183.00. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $21.84 billion in 2025, with consistent earnings beats in recent quarters, including Q3 2026 EPS of $3.23 beating estimates. The company maintains a dividend of $1.05 per share and recently raised full-year guidance, reflecting operational strength amid tariff pressures.
Outlook remains positive with raised profit guidance and segment growth, but risks include margin pressure from tariffs and a product recall. Analyst sentiment is mixed with 47% buy ratings, suggesting cautious optimism. The stock offers stability as a Dividend Aristocrat with growth catalysts from medical technology advancements, though investors should monitor margin trends and competitive dynamics.
MSTZ trades at $11.27, up 4.16% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Financial ratios are unavailable, limiting fundamental assessment. Recent news highlights ETF performance unrelated to MSTZ, with no direct company updates provided.
The outlook is cautious due to bearish technicals and lack of fundamental data. Risks include market volatility and unverified financial health. Investment opportunity hinges on future earnings clarity and positive analyst coverage, which are currently absent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
